Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEN6X7)

Drug Name
Atropine Drug Info
Synonyms
dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate
Indication
Disease Entry ICD 11 Status REF
Organophosphate poisoning NE6Z Approved [1]
Poison intoxication NE6Z Phase 1 [1]
Therapeutic Class
Antiarrhythmic Agents
Cross-matching ID
PubChem CID
174174
ChEBI ID
CHEMBL254656
CAS Number
CAS 51-55-8
TTD Drug ID
DMEN6X7
VARIDT Drug ID
DR00665
ACDINA Drug ID
D00851

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Muscarinic acetylcholine receptor M5 (CHRM5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Promazine DMZAL7W Acute intermittent hepatic porphyria 5C58.11 Approved [9]
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [10]
Pilocarpine DMV9ADG Glaucoma/ocular hypertension 9C61 Approved [11]
Anisodine DMNOSWU Central and peripheral nervous disease 8A04-8E7Z Approved [12]
Propiverine DMUWBIJ Urinary incontinence MF50.2 Approved [13]
Umeclidinium DM4E8O9 Chronic obstructive pulmonary disease CA22 Approved [14]
Cimetropium bromide DMZHPNE Gastric motility disorder DA21 Approved [15]
Butylscopolamine DMZKXB7 Dysmenorrhea GA34.3 Approved [16]
Trospium DMX6RTG Overactive bladder GC50.0 Approved [17]
Choline alfoscerate DMOI1ZF Amnesia MB21.1 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic cation transporter 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [19]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [20]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [21]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [22]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [23]
Verapamil DMA7PEW Angina pectoris BA40 Approved [24]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [25]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [26]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [27]
Propranolol DM79NTF Angina pectoris BA40 Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [29]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [5]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [5]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [30]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [29]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [5]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [31]
Gefitinib DM15F0X Colon adenocarcinoma Approved [29]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [32]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Antileukoproteinase (SLPI)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [4]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [4]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [33]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [4]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [4]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [4]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [4]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [34]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [4]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By DNA replication licensing factor MCM4 (MCM4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [35]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [36]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [41]
Testosterone DM7HUNW Hot flushes GA30 Approved [42]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [42]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-A1 (CCNA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [44]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [46]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [47]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [45]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [48]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Folic Acid DMEMBJC Colorectal carcinoma Approved [50]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By NACHT, LRR and PYD domains-containing protein 3 (NLRP3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [52]
Selenium DM25CGV N. A. N. A. Approved [53]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [34]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [54]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [55]
Testosterone DM7HUNW Hot flushes GA30 Approved [56]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [57]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [58]
Ethanol DMDRQZU Chronic pain MG30 Approved [59]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [60]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [60]
Norepinephrine DMOUC09 Alopecia ED70 Approved [60]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [61]
Quercetin DM3NC4M Obesity 5B81 Approved [62]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [63]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [66]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [67]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [4]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [5]
Cyclin-A1 (CCNA1) OTX4HD45 CCNA1_HUMAN Gene/Protein Processing [6]
DNA replication licensing factor MCM4 (MCM4) OT19PNNG MCM4_HUMAN Gene/Protein Processing [6]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) OTZM6MHU NLRP3_HUMAN Gene/Protein Processing [7]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Regulation of Drug Effects [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 320).
2 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
3 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
4 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
5 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
6 Gene expression signature of parathion-transformed human breast epithelial cells. Int J Mol Med. 2007 May;19(5):741-50.
7 Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
8 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
9 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
10 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
11 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
12 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
13 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
15 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
16 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
17 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
19 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
20 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
21 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
22 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
23 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
24 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
25 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
26 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
27 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
28 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
29 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
30 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
31 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
32 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
33 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
34 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
35 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
36 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
37 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
38 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
39 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
40 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
41 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
42 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
43 Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
44 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
45 Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
46 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
47 Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting. Biol Pharm Bull. 2010;33(5):743-51. doi: 10.1248/bpb.33.743.
48 Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
49 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
50 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
51 A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec;3(12):e486. doi: 10.1371/journal.pmed.0030486.
52 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
53 Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
54 AS3MT facilitates NLRP3 inflammasome activation by m(6)A modification during arsenic-induced hepatic insulin resistance. Cell Biol Toxicol. 2023 Oct;39(5):2165-2181. doi: 10.1007/s10565-022-09703-7. Epub 2022 Feb 28.
55 Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
56 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
57 Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
58 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
59 Pterostilbene attenuates RIPK3-dependent hepatocyte necroptosis in alcoholic liver disease via SIRT2-mediated NFATc4 deacetylation. Toxicology. 2021 Sep;461:152923. doi: 10.1016/j.tox.2021.152923. Epub 2021 Aug 30.
60 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
61 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
62 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
63 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
64 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
65 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
66 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
67 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.